Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

GILEAD SCIENCES, INC.

(GILD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Insider Trends: Gilead Sciences Insider Converts Option/Derivative Security to Acquire Stock, Makes Tax Sale, Selling Trend Intact

06/14/2021 | 04:55pm EDT


ę MT Newswires 2021
All news about GILEAD SCIENCES, INC.
07/30SECTOR UPDATE : Health Care Stocks Scratching Out Small Advance Just Ahead of Fr..
MT
07/30GILEAD SCIENCES : SVB Leerink Adjusts Price Target on Gilead Sciences to $77 Fro..
MT
07/30GLOBAL MARKETS LIVE : Caterpillar, Chevron, Robinhood, Bayer, Gilead Sciences...
07/30GILEAD SCIENCES : BMO Capital Adjusts Gilead Sciences' Price Target to $72 From ..
MT
07/30Today on Wall Street: Without a care in the world
07/30GILEAD SCIENCES : RBC Boosts Price Target on Gilead Sciences to $84 From $81, Ma..
MT
07/30ANALYST RECOMMENDATIONS : Amazon, Barclays, Comcast, Next, Pfizer...
07/29IGM BIOSCIENCES : Names New Chief Medical Officer
MT
07/29GILEAD SCIENCES : View Second Quarter 2021 Prepared Remarks
PU
07/29GILEAD SCIENCES : ANNOUNCES SECOND QUARTER 2021 FINANCIAL RESULTS (Form 8-K)
PU
More news
Financials (USD)
Sales 2021 24 991 M - -
Net income 2021 6 614 M - -
Net Debt 2021 23 758 M - -
P/E ratio 2021 13,3x
Yield 2021 4,01%
Capitalization 85 648 M 85 648 M -
EV / Sales 2021 4,38x
EV / Sales 2022 4,29x
Nbr of Employees 13 600
Free-Float 99,9%
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | MarketScreener
Technical analysis trends GILEAD SCIENCES, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 31
Last Close Price 68,29 $
Average target price 75,72 $
Spread / Average Target 10,9%
EPS Revisions
Managers and Directors
Daniel P. O'Day Chairman & Chief Executive Officer
Andrew D. Dickinson Chief Financial Officer
Merdad V. Parsey Chief Medical Officer
Flavius Martin Executive Vice President-Research
Brett A. Pletcher Secretary, Chief Compliance Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
GILEAD SCIENCES, INC.17.22%85 648
BIONTECH SE302.78%79 303
WUXI APPTEC CO., LTD.33.61%59 516
REGENERON PHARMACEUTICALS18.94%59 505
VERTEX PHARMACEUTICALS-14.71%52 296
GENMAB A/S15.10%29 546